AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

AbbVie recently received FDA approval for Juvmo (tavapadon), a new once-daily Parkinson's pill. This approval is significant as Juvmo is a key asset from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, designed to strengthen its neuroscience pipeline. The drug offers a new treatment option for Parkinson's patients by selectively activating D1/D5 dopamine receptors and is expected to contribute to AbbVie's growing neuroscience portfolio, with projected annual sales of $1.4 billion by 2